DHR vs KYTX · P/E 39, rev $6.26B vs $488.8M cap
Danaher Corporation (DHR) versus Kyverna Therapeutics, Inc. Common Stock (KYTX) — a side-by-side from cached financials, not a winner call.
Danaher Corporation (DHR) is a diagnostics & research company listed on US.
Kyverna Therapeutics, Inc. Common Stock (KYTX) is a biotechnology company listed on NASDAQ.
Latest reported DHR revenue for 2026-06-26 was $6.26B. Net income was $870.0M. Revenue was up 5.3% from 2026-03-27 to 2026-06-26. DHR currently screens at market cap $144.18B and trailing P/E 39.0.
KYTX does not have a complete income-statement cache yet.
DHR currently screens at market cap $144.18B and trailing P/E 39.0. KYTX currently screens at market cap $488.8M.
Not investment advice. Open the DHR and KYTX stock pages for the full models.
Not investment advice.